Literature DB >> 16397445

Diagnosis and treatment of temporal lobe epilepsy.

Orrin Devinsky1.   

Abstract

Of the 1,200,000 Americans with partial epilepsy, temporal lobe epilepsy (TLE) occurs in more than 400,000. Temporal lobe seizures are usually stereotypic in their symptoms and duration. A typical sequence is an aura followed by arrest of motor behavior, blank stare, and automatisms. Patients with TLE often show impairments in attention, memory, mental processing speed, executive functions, mood, personality, and drive-related behaviors. Interictal depression occurs in approximately one third of TLE patients. TLE is diagnosed by a history of characteristic partial seizure symptoms. The diagnosis is confirmed by the capture of a typical episode during an electroencephalogram (EEG) or video-EEG, with epileptiform activity over one or both temporal regions. Video-EEG monitoring has revolutionized diagnosis and should be considered in patients in whom diagnosis is uncertain. TLE is treated with medications, resective surgery, and vagus nerve stimulation. Epilepsy surgery should be considered in all patients with refractory partial epilepsy.

Entities:  

Mesh:

Year:  2004        PMID: 16397445

Source DB:  PubMed          Journal:  Rev Neurol Dis        ISSN: 1545-2913


  24 in total

Review 1.  Seizure detection: do current devices work? And when can they be useful?

Authors:  Xiuhe Zhao; Samden D Lhatoo
Journal:  Curr Neurol Neurosci Rep       Date:  2018-05-23       Impact factor: 5.081

Review 2.  Role of oxidative stress in epileptic seizures.

Authors:  Eun-Joo Shin; Ji Hoon Jeong; Yoon Hee Chung; Won-Ki Kim; Kwang-Ho Ko; Jae-Hyung Bach; Jau-Shyong Hong; Yukio Yoneda; Hyoung-Chun Kim
Journal:  Neurochem Int       Date:  2011-06-13       Impact factor: 3.921

3.  Epilepsy surgery trends in the United States, 1990-2008.

Authors:  D J Englot; D Ouyang; P A Garcia; N M Barbaro; E F Chang
Journal:  Neurology       Date:  2012-03-21       Impact factor: 9.910

Review 4.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

Review 5.  GABA-ergic cell therapy for epilepsy: Advances, limitations and challenges.

Authors:  Ashok K Shetty; Dinesh Upadhya
Journal:  Neurosci Biobehav Rev       Date:  2015-12-31       Impact factor: 8.989

Review 6.  Ionotropic glutamate receptors & CNS disorders.

Authors:  Derek Bowie
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-04       Impact factor: 4.388

Review 7.  Is exposure to enriched environment beneficial for functional post-lesional recovery in temporal lobe epilepsy?

Authors:  Anandh Dhanushkodi; Ashok K Shetty
Journal:  Neurosci Biobehav Rev       Date:  2007-11-28       Impact factor: 8.989

8.  Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases.

Authors:  Chien-Liang Glenn Lin; Qiongman Kong; Gregory D Cuny; Marcie A Glicksman
Journal:  Future Med Chem       Date:  2012-09       Impact factor: 3.808

9.  Cortical deactivation induced by subcortical network dysfunction in limbic seizures.

Authors:  Dario J Englot; Badri Modi; Asht M Mishra; Matthew DeSalvo; Fahmeed Hyder; Hal Blumenfeld
Journal:  J Neurosci       Date:  2009-10-14       Impact factor: 6.167

10.  Variations of ATP and its metabolites in the hippocampus of rats subjected to pilocarpine-induced temporal lobe epilepsy.

Authors:  Flávia Doná; Isaltino Marcelo Conceição; Henning Ulrich; Eliane Beraldi Ribeiro; Thalma Ariani Freitas; Ana Leonor Abrahao Nencioni; Maria José da Silva Fernandes
Journal:  Purinergic Signal       Date:  2016-03-03       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.